ST. LOUIS, Jan. 5, 2012 /PRNewswire/ -- Veniti, a startup company focused on the treatment of venous disease, announced today it has added Scott Solano to its executive team as Chief Operating Officer (COO). Solano joins Veniti with more than 22 years of experience designing, testing and producing medical devices, including eight years of executive management experience for medical device companies. He will oversee the development of Veniti's suite of venous products.
"We are fortunate to have someone as talented as Scott on board to direct our operations and research and development programs," said Sean Morris, Veniti's President and CEO. "Scott's experience and management capabilities are second to none in the endovascular industry, as demonstrated in the success of his previous endeavors. We welcome him to our executive team and look forward to his contributions to Veniti to advance the diagnosis and treatment of venous disease."
Prior to joining Veniti, Solano was the Senior Vice President and Chief Technology Officer at AngioDynamics, Inc., where he was responsible for all aspects of R&D, Process Engineering and Clinical Trials. He also served as company's interim CEO in 2011.
Earlier in his career, Solano served as President, CEO and Chairman for Arterial Vascular Engineering (AVE), a company for which he wrote the business plan and lined up initial investors. Under his leadership, AVE went public and was ultimately acquired by Medtronic for over $4 billion. Solano led the high growth public company from less than 200 employees to more than 4,500 employees in four years, while also taking quarterly revenues from less than $22 million to more than $230 million.
"Being in the industry, I watched Veniti get its start as Sean and his lead investors strategically assembled the company's initial product line with three distinctive devices," said Solano. "In addition to growing awareness among the medical community, there are demographic trends that support the need for venous disease solutions. What excites me most about this company is that the venous intervention market is underserved and presents a lot of opportunity for Veniti to make a name for itself and own the market."
Veniti raised over $15 million in venture financing in 2011, led by Baird Venture Partners and H&Q Healthcare Investors (NYSE: HQH) and H&Q life Sciences Investors (NYSE: HQL).
Veniti is a medical device company singularly focused on the venous disease space through the development and marketing of a range of premium innovative products that provide comprehensive treatment across the continuum of venous disease. Veniti products are all made in the USA. Research, development and manufacturing are conducted in Silicon Valley while the company's leadership is headquartered in St. Louis. For more information, call 314.282.3753 or visit www.venitimedical.com.